

(19)



(11)

**EP 3 581 206 B8**

(12)

**CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:  
**Corrected version no 1 (W1 B1)**  
**Corrections, see**  
**Bibliography INID code(s) 72**

(48) Corrigendum issued on:  
**19.02.2025 Bulletin 2025/08**

(45) Date of publication and mention  
of the grant of the patent:  
**25.12.2024 Bulletin 2024/52**

(21) Application number: **19173675.0**

(22) Date of filing: **20.10.2011**

(51) International Patent Classification (IPC):  
**A61K 47/68** <sup>(2017.01)</sup>      **A61K 31/498** <sup>(2006.01)</sup>  
**A61K 31/519** <sup>(2006.01)</sup>      **A61K 31/4745** <sup>(2006.01)</sup>  
**A61K 31/5377** <sup>(2006.01)</sup>      **A61K 31/4375** <sup>(2006.01)</sup>  
**A61K 31/436** <sup>(2006.01)</sup>      **A61K 45/06** <sup>(2006.01)</sup>  
**A61P 35/00** <sup>(2006.01)</sup>      **A61P 35/02** <sup>(2006.01)</sup>

(52) Cooperative Patent Classification (CPC):  
**A61K 47/6811; A61K 31/436; A61K 31/4375;**  
**A61K 31/4745; A61K 31/498; A61K 31/519;**  
**A61K 31/5377; A61K 45/06; A61K 47/6849;**  
**A61K 47/6867; A61P 35/00; A61P 35/02;**  
**A61P 43/00**

(54) **SYNERGISTIC EFFECTS BETWEEN AURISTATIN-BASED ANTIBODY DRUG CONJUGATES AND INHIBITORS OF THE PI3K-AKT MTOR PATHWAY**

SYNERGIEWIRKUNG ZWISCHEN AURISTATIN-BASIERTEN

ANTIKÖRPER-WIRKSTOFFKONJUGATEN UND HEMMERN DES PI3K-AKT-MTOR-WEGS

EFFETS SYNERGIQUES ENTRE DES CONJUGUÉS D'ANTICORPS ET DE MÉDICAMENT À BASE D'AURISTATINE ET DES INHIBITEURS DE LA VOIE PI3K-AKT-MTOR

(84) Designated Contracting States:  
**AL AT BE BG CH CY CZ DE DK EE ES FI FR GB**  
**GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO**  
**PL PT RO RS SE SI SK SM TR**

(30) Priority: **22.10.2010 US 40576710 P**  
**23.02.2011 US 201161445785 P**

(43) Date of publication of application:  
**18.12.2019 Bulletin 2019/51**

(62) Document number(s) of the earlier application(s) in  
accordance with Art. 76 EPC:  
**11835158.4 / 2 629 801**

(73) Proprietor: **Seagen Inc.**  
**Bothell, WA 98021 (US)**

(72) Inventors:  
• **LEWIS, Timothy S.**  
**Bothell, WA Washington 98021 (US)**  
• **LAW, Che-Leung**  
**Bothell, WA Washington 98021 (US)**  
• **MCEARCHERN, Julie A.**  
**Bothell, WA Washington 98021 (US)**

(74) Representative: **Abel & Imray LLP**  
**Westpoint Building**  
**James Street West**  
**Bath BA1 2DA (GB)**

(56) References cited:  
**WO-A1-2009/048967 WO-A1-2009/117531**

- **MCEARCHERN ET AL.:** "Activity of SGN-35 in Preclinical Models of Combination Therapy and Relapse Prevention", **HAEMATOLOGICA, THE HEMATOLOGY JOURNAL**, vol. 95, no. S4, 31 October 2010 (2010-10-31), XP002731348, Retrieved from the Internet <URL:http://www.haematologica.org/content/haematol/95/supplement\_4/S1.full.pdf> [retrieved on 20141002]
- **CHESON B D:** "Novel therapies for peripheral T-cell non-Hodgkin's lymphomas", **CURRENT OPINION IN HEMATOLOGY, RAPID SCIENCE PUBLISHERS, PHILADELPHIA, PA, US**, vol. 16, no. 4, 1 July 2009 (2009-07-01), pages 299 - 305, XP008172491, ISSN: 1065-6251, DOI: 10.1097/MOH.0B013E32832AD69A

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

**EP 3 581 206 B8**

- PATRICK B. JOHNSTON ET AL: "A Phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma", AMERICAN JOURNAL OF HEMATOLOGY, vol. 85, no. 5, 1 January 2010 (2010-01-01), pages NA - NA, XP055123462, ISSN: 0361-8609, DOI: 10.1002/ajh.21664
- YOUNES ET AL: "Multiple complete responses in a phase 1 dose-escalation study of the antibody-drug conjugate SGN-35 in patients with relapsed or refractory CD30-positive lymphomas", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, vol. 112, no. 11, 1 January 2008 (2008-01-01), pages 1006, XP008170898, ISSN: 0006-4971
- JONA A ET AL: "Novel treatment strategies for patients with relapsed classical Hodgkin lymphoma", BLOOD REVIEWS, CHURCHILL LIVINGSTONE, AMSTERDAM, NL, vol. 24, no. 6, 15 September 2010 (2010-09-15), pages 233 - 238, XP027471337, ISSN: 0268-960X, [retrieved on 20101101], DOI: 10.1016/J.BLRE.2010.08.003
- T.S. LEWIS ET AL.: "Auristatin-based antibody-drug conjugates are synergistic in combination with PI3K-AKT-mTOR pathway inhibitors in hematologic malignancies and carcinoma", CANCER RESEARCH, vol. 71, no. S1, 15 April 2011 (2011-04-15), XP002731350, Retrieved from the Internet <URL:[http://cancerres.aacrjournals.org/cgi/content/short/71/8\\_MeetingAbstracts/1789](http://cancerres.aacrjournals.org/cgi/content/short/71/8_MeetingAbstracts/1789)> [retrieved on 20141001]